Modern management of sarcoidosis: treatment is increasingly tailored to risk

Modern management of sarcoidosis: treatment is increasingly tailored to risk

Publication date on this website: 7 October 2026.
Date of the original paper: 2026.

Introduction
This new review provides a contemporary overview of the diagnosis, assessment of disease activity, and treatment of sarcoidosis. It emphasizes the heterogeneity of the disease, the need for risk assessment, and the stepwise selection of treatment according to the organs involved, symptoms, and the possibility of permanent damage.

Extended summary
The authors describe sarcoidosis as a multisystem granulomatous disease that can follow very different patterns. Clinical assessment therefore includes information about symptoms and affected organs, imaging, lung function, laboratory findings, and, when needed, histopathological confirmation and targeted tests for other possible causes of granulomatous inflammation.

The review emphasizes that treatment decisions should not be based on a single finding. In patients without significant risk, careful monitoring may sometimes be appropriate, whereas medication and regular assessment of response are needed when organ function is threatened, symptoms are pronounced, or the disease is progressing. Corticosteroids can be effective in reducing inflammation, but long-term exposure carries cumulative risks. For this reason, corticosteroid-sparing medications and targeted therapies are increasingly being considered, with an individual assessment of benefits and risks.

What is new
The modern approach shifts the focus from one universal algorithm toward phenotyping and risk assessment. In practice, this means combining the clinical course, affected organ, functional measurements, radiological findings, and treatment burden. Biomarkers and more precise prediction models remain important areas of research, but they are not yet a substitute for a comprehensive clinical assessment.

Why it matters to people with sarcoidosis and clinicians
For people with sarcoidosis, the review may help explain why treatment decisions differ from person to person and why follow-up is important even when symptoms are mild. For clinicians, it provides a framework for considering risk, monitoring activity, and reducing unnecessary long-term exposure to corticosteroids. It is particularly important to recognize patients with a potentially progressive or organ-threatening course in a timely manner.

Limitations of the evidence
This is a review article, and its recommendations rely on a combination of guidelines, clinical studies, observational data, and expert consensus. The evidence is not equally strong for all organ manifestations and treatments. Differences between patients and healthcare systems make it difficult to apply every conclusion directly to an individual.

Conclusion
Sarcoidosis is best managed according to risk, disease activity, and the affected organ, with regular reassessment. The goal is to control the disease with the least possible long-term treatment burden, in collaboration with the treating physician and, when needed, a multidisciplinary team.

Source and bibliographic details
Sarcoidosis: current concepts in diagnosis, assessment and management. Frontiers in Medicine. 2026;13:1878683. DOI: 10.3389/fmed.2026.1878683.
Source: https://doi.org/10.3389/fmed.2026.1878683

Medical note
This text is for informational purposes and does not replace a medical examination, diagnosis, or individualized medical advice. Do not start, stop, or change treatment independently. Decisions about monitoring and treatment should be made with the doctor who knows your overall health condition.